Larimar TherapeuticsSTU:ZA71 34 Pretax Margin % is % as of Mar. 2026. GuruFocus rates STU:ZA71 with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 940 Biotechnology companies, Larimar Therapeutics ranks worse than 106382.87% on this metric.
The historical rank and industry rank for Larimar Therapeutics's Pretax Margin % or its related term are showing as below:
STU:ZA71's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.895 * Ranked among companies with meaningful Pretax Margin % only.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Larimar Therapeutics Pretax Margin % Related Terms
Larimar Therapeutics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Larimar Therapeutics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:ZA71 vs XFOR, CMPX, PROK: Pretax Margin % Comparison
For the Biotechnology subindustry, Larimar Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Larimar Therapeutics Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Larimar Therapeutics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Larimar Therapeutics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Larimar Therapeutics (STU:ZA71) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Larimar Therapeutics and its competitors. According to the industry distribution chart, Larimar Therapeutics ranks #999999 out of 940 companies in the Biotechnology industry.
Is Larimar Therapeutics' Pretax Margin % too high?
Larimar Therapeutics' current Pretax Margin % is %. Based on the distribution chart, Larimar Therapeutics ranks #999999 out of 940 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Larimar Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Larimar Therapeutics' Pretax Margin % compare to XFOR and CMPX?
According to the Biotechnology industry distribution chart, Larimar Therapeutics ranks #999999 out of 940 companies for Pretax Margin %. This places Larimar Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Larimar Therapeutics and its competitors. Larimar Therapeutics's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Larimar Therapeutics stock overvalued right now?
Larimar Therapeutics (STU:ZA71) has a current Pretax Margin % of %. The current Pretax Margin % is %. Larimar Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Larimar Therapeutics (STU:ZA71), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
34GF Score
Get the complete analysis for STU:ZA71
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ZA71 has been successfully added to your 
